Despite improved treatment, cardiovascular disease remains one of the most common diseases and causes of death in the Western world. Hypercholesterolemia is a well known risk factor for developing cardiovascular disease. Prevention and treatment are based in part on lowering LDL cholesterol. Dietary and lifestyle changes always play an important part of the treatment and preventive effort, and conversion to a heart-healthy diet reduces LDL cholesterol by a mean 10%. Further lowering of LDL cholesterol by means of food supplements have been demonstrated in numerous studies. Cholesterol lowering food supplements include isolated soy protein and water soluble dietary fibre such as psyllium husks. Postulated mechanisms of action responsible for the cholesterol lowering in these two food supplements are different, so there is a reason to expect an additive cholesterol lowering effect during concomitant treatment with both substances. The investigators want to investigate whether concomitant treatment with psyllium husks and isolated soy protein in addition to a heart-healthy diet results in a significantly greater reduction of LDL cholesterol in hypercholesterolemia, than single treatment with each of the substances.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
41
Oral suspension, oral use, two daily dosages consisting of 5 grams each
Oral suspension, oral use, 30 grams once per day
Oral suspension, oral use, 30 grams once per day
Oral suspension, oral use, two daily dosages consisting of 5 grams each
The Lipid Clinic, Aalborg Hospital
Aalborg, RN, Denmark
Change from baseline in LDL cholesterol at 6 weeks
3rd and 4th visits equal the ends of the 1st and 2nd intervention period at +6 weeks and +16 weeks from baseline respectively (4 week wash-out period in between the intervention periods). 2nd visit includes randomization and baseline measurement, while 1st visit @ -4 weeks compared to baseline includes screening and inclusion
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in total cholesterol at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in HDL cholesterol at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in triglycerides at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in fasting plasma glucose at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in body weight at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in apolipoprotein B at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in small, dense LDL cholesterol at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
Change from baseline in high sensitive CRP at 6 weeks
Time frame: 3rd and 4th visits at the investigational site
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.